To access this material please log in or register

Register Authorize

Ranolazine and arrhythmias

Tatarsky B. A.
Federal State Budgetary Institution, “North-West Federal Medical Research Center” of the RF Ministry of Health Care, Akkuratova 2, St.-Petersburg 197341

Keywords: treatment, heart rhythm disturbances, ranolazine

DOI: 10.18087/rhj.2013.6.1857

The review is focused on principles of sodium channel functioning; relationship of these principles with the sodium shift and intracellular calcium; pharmacological features of ranolazine; its anti-arrhythmic capability; and experimental and scarce clinical data on the anti-arrhythmic effect of ranolazine, the late sodium channel blocker.
  1. Fox K, Garcia MA, Ardissino D et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27 (11):1341–1381.
  2. Ross H, Kowey P, Naccarelli G. New antiarrhythmic pharmacologic therapies and regulatory issues in antiarrhythmic drug deve­lopment. In Wang, P (editor); New Arrhythmia Technologies; Blackwell Publishing; In Press, 2005.
  3. Camm J, Kirchhof P, Lip G. Atrial fibrillation. In: The ESC Textbook of Cardiology, edited by Camm J, Luscher T 2009.
  4. Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace. 2008;10 (6):647–665.
  5. Kirchhof P, Bax J, Blomstrom-Lundquist C et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. Eur Heart J. 2009;30 (24):2969–2977.
  6. Viskin S, Barron HV, Heller K et al. The treatment of atrial fibrillation: pharmacologic and nonpharmacologic strategies. Curr Probl Cardiol. 1997;22 (2):37–108.
  7. Burashnikov A, Antzelevitch C. Can inhibition of IKur promote atrial fibrillation? Heart Rhythm. 2008;5 (9):1304–1309.
  8. Matsuda T, Masumiya H, Tanaka N et al. Inhibition by a novel anti-arrhythmic agent, NIP-142, of cloned human cardiac K+ channel Kv1.5 current. Life Sci. 2001;68 (17):2017–2024.
  9. Mazzini MJ, Monahan KM. Pharmacotherapy for atrial arrhythmias: present and future. Heart Rhythm. 2008;5 (6 Suppl): S26–31.
  10. Naccarelli GV. Antiadrenergic therapy in the control of atrial fibrillation. J Cardiovasc Pharmacol Ther 2005;10 (Suppl 1):S33–43.
  11. Falk RH. Pharmacologic control of heart rate in atrial fibrillation. Cardiol Clin. 1996;14 (4):521–36.
  12. Burashnikov A, Di Diego JM, Zygmunt AC et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007;116 (13):1449–1457.
  13. Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibi­ting late sodium current. J Cardiovasc Electrophysiol. 2006;17 (Suppl 1):S169‑S177.
  14. Sicouri S, Glass A, Antzelevitch C. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations.Heart Rhythm. 2008;5 (7):1019–1026.
  15. Sossalla S, Kallmeyer B, Wagner S et al. Altered Naþ currents in atrial fibrillation: effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol. 2010;55 (21):2330–2342.
  16. Antzelevitch C, Burashnikov A, Sicouri S. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm. 2011;8 (8):1281–1290.
  17. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E et al. MERLIN–TIMI 36 Investigators. Evaluation of a novel anti-ische­mic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN) – TIMI 36 trial. JAMA. 2007;297 (16):1775–1783.
  18. Murdock D, Overton N, Kersten M. et al. The effect of ranolazine on maintaining sinus rhythm in patient with resistant atrial fibrillation. Indian Pacing Electrophysiol J.2008;8 (3):175–181.
  19. Murdock DK, Kersten M, Kaliebe J, Larrain G. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible «pill in the pocket» approach to atrial fibrillation. Indian Pacing Electrophysiol J. 2009;9 (5):260–267.
  20. Татарский Б. А. Использование блокатора поздних натриевых каналов при купировании фибрилляции предсердий (пилотное исследование. Сердце. 2013;12 (2):129–133.
  21. Boriani G, Biffi M, Capucci A et al. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without under­lying heart disease. A randomized controlled trial. Ann Intern Med. 1997;126 (8):621–625.
  22. Miles R, Passman R, Murdock D. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 2011;108 (5):673–676.
  23. Schotten U, Verheule S, Kerfant BG, Greiser M. Enhanced late Na currents in atrial fibrillation: new drug target or just an epipheno­menon? J Am Coll Cardiol. 2010;55 (21):2343–2345.
  24. Wang P, Fraser H, Lloyd S et al. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J Pharmacol Exp Ther. 2007;321 (1): 213–220.
  25. Carlsson L, Chartier D, Nattel S. Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent in atrial and ventricular tissue of the dog. J Cardiovasc Pharmacol. 2006;47 (1):123–132.
  26. Lemoine M, Duverger J, Naud P et al. Arrhythmogenic left atrial cellular electrophysiology in a murine genetic long QT syndrome model. Cardiovasc Res. 2011;92 (1):67–74.
  27. Burashnikov A, Sicouri S, Antzelevitch C. et al. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol. 2010;56 (15):1216–1224.
  28. Dhalla AK, Wang WQ, Dow J et al. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2009;297 (5):H1923–1929.
  29. Kloner RA, Dow JS, Bhandari A. First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia / reperfusion model. J Cardiovasc Pharmacol Ther. 2011;16 (2):192–196.
  30. Antoons G, Oros A, Beekman JD et al. Late Na current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. J Am Coll Cardiol. 2010;55 (8):801–809
  31. Moss AJ, Zareba W, Schwarz KQ et al. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol. 2008;19 (12):1289–1293.
Tatarsky B. A. Ranolazine and arrhythmias. Russian Heart Journal. 2013;12(6):378-384

To access this material please log in or register

Register Authorize
Ru En